BE2013C038I2 - - Google Patents
Download PDFInfo
- Publication number
- BE2013C038I2 BE2013C038I2 BE2013C038C BE2013C038C BE2013C038I2 BE 2013C038 I2 BE2013C038 I2 BE 2013C038I2 BE 2013C038 C BE2013C038 C BE 2013C038C BE 2013C038 C BE2013C038 C BE 2013C038C BE 2013C038 I2 BE2013C038 I2 BE 2013C038I2
- Authority
- BE
- Belgium
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200301129 | 2003-08-05 | ||
US49545103P | 2003-08-14 | 2003-08-14 | |
EP04739008A EP1660531A2 (en) | 2003-08-05 | 2004-07-22 | Novel insulin derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
BE2013C038I2 true BE2013C038I2 (un) | 2023-12-14 |
Family
ID=34117520
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BE2013C035C BE2013C035I2 (un) | 2003-08-05 | 2013-06-11 | |
BE2013C038C BE2013C038I2 (un) | 2003-08-05 | 2013-06-19 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BE2013C035C BE2013C035I2 (un) | 2003-08-05 | 2013-06-11 |
Country Status (18)
Country | Link |
---|---|
US (3) | US7615532B2 (un) |
EP (3) | EP1660531A2 (un) |
JP (1) | JP4463814B2 (un) |
KR (1) | KR101159559B1 (un) |
AU (2) | AU2004261353B2 (un) |
BE (2) | BE2013C035I2 (un) |
BR (1) | BRPI0413276B8 (un) |
CA (1) | CA2531988C (un) |
CY (3) | CY1113850T1 (un) |
FR (1) | FR13C0035I2 (un) |
HU (1) | HUS1300033I1 (un) |
IL (1) | IL172980A (un) |
LU (2) | LU92213I2 (un) |
MX (1) | MXPA06001283A (un) |
NO (3) | NO340925B1 (un) |
PL (1) | PL2107069T3 (un) |
RU (1) | RU2518460C2 (un) |
WO (1) | WO2005012347A2 (un) |
Families Citing this family (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2328579T3 (es) * | 2003-07-25 | 2009-11-16 | Conjuchem Biotechnologies Inc. | Derivados de insulina de larga duracion y procedimientos asociados. |
BRPI0413276B8 (pt) * | 2003-08-05 | 2021-05-25 | Novo Nordisk As | derivado de insulina, complexo de zinco do mesmo, e, composição farmacêutica |
WO2006082204A1 (en) | 2005-02-02 | 2006-08-10 | Novo Nordisk A/S | Insulin derivatives |
US20080171695A1 (en) | 2005-02-02 | 2008-07-17 | Novo Nordisk A/S | Insulin Derivatives |
EP2505593A1 (en) * | 2005-12-28 | 2012-10-03 | Novo Nordisk A/S | Compositions comprising an acylated insulin and zinc and method of making the said compositions |
ATE482977T1 (de) | 2006-02-27 | 2010-10-15 | Novo Nordisk As | Insulinderivate |
WO2007104736A2 (en) * | 2006-03-13 | 2007-09-20 | Novo Nordisk A/S | Acylated single chain insulin |
WO2007127236A2 (en) | 2006-04-28 | 2007-11-08 | Acrymed, Inc. | Antimicrobial site dressings |
US8796205B2 (en) | 2006-05-09 | 2014-08-05 | Novo Nordisk A/S | Insulin derivative |
CN101437849B (zh) * | 2006-05-09 | 2015-09-30 | 诺沃-诺迪斯克有限公司 | 胰岛素衍生物 |
KR101441444B1 (ko) * | 2006-05-09 | 2014-09-18 | 노보 노르디스크 에이/에스 | 인슐린 유도체 |
JP5097900B2 (ja) * | 2006-06-27 | 2012-12-12 | 独立行政法人物質・材料研究機構 | 有機酸又はこれらの誘導体の活性エステル体の製造方法 |
ES2542146T3 (es) * | 2006-07-31 | 2015-07-31 | Novo Nordisk A/S | Insulinas extendidas PEGiladas. |
KR101699370B1 (ko) | 2006-09-22 | 2017-02-14 | 노보 노르디스크 에이/에스 | 프로테아제 내성 인슐린 유사체 |
CN101674812B (zh) | 2007-04-30 | 2013-12-11 | 诺沃-诺迪斯克有限公司 | 干燥蛋白组合物的方法、干燥的蛋白组合物和包含干燥的蛋白的药物组合物 |
WO2008145730A1 (en) * | 2007-06-01 | 2008-12-04 | Novo Nordisk A/S | Stable non-aqueous pharmaceutical compositions |
EP2514406A1 (en) | 2007-06-01 | 2012-10-24 | Novo Nordisk A/S | Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier |
WO2008152106A1 (en) * | 2007-06-13 | 2008-12-18 | Novo Nordisk A/S | Pharmaceutical formulation comprising an insulin derivative |
EP2178912B1 (en) * | 2007-08-15 | 2015-07-08 | Novo Nordisk A/S | Insulin analogues with an acyl and aklylene glycol moiety |
ES2526924T3 (es) | 2007-08-15 | 2015-01-16 | Novo Nordisk A/S | Insulinas con una fracción acilo que comprende unidades repetitivas de aminoácidos que contienen alquilenglicol |
CN101157725B (zh) * | 2007-10-24 | 2012-07-25 | 中国药科大学 | 人胰岛素类似物的制备方法及用途 |
US8710000B2 (en) | 2007-11-08 | 2014-04-29 | Novo Nordisk A/S | Insulin derivative |
ES2430042T3 (es) | 2007-11-16 | 2013-11-18 | Novo Nordisk A/S | Composiciones farmacéuticas estables que comprenden liraglutida y degludec |
EP2254905B1 (en) | 2008-03-14 | 2016-12-14 | Novo Nordisk A/S | Protease-stabilized insulin analogues |
WO2009115469A1 (en) | 2008-03-18 | 2009-09-24 | Novo Nordisk A/S | Protease stabilized, acylated insulin analogues |
CN102149411A (zh) | 2008-09-12 | 2011-08-10 | 诺沃—诺迪斯克有限公司 | 酰化肽或蛋白的方法 |
ES2607003T3 (es) | 2008-10-30 | 2017-03-28 | Novo Nordisk A/S | Tratamiento de diabetes mellitus utilizando inyecciones de insulina con una frecuencia de inyección inferior a la diaria |
US9480753B2 (en) | 2009-01-23 | 2016-11-01 | Novo Nordisk A/S | FGF21 derivatives with albumin binder A-B-C-D-E- and their use |
EP2493919A1 (en) | 2009-10-30 | 2012-09-05 | Novo Nordisk A/S | Derivatives of cgrp |
WO2011086093A2 (en) | 2010-01-12 | 2011-07-21 | Novo Nordisk A/S | Pharmaceutical compositions for oral administration of insulin peptides |
CN102812039B (zh) | 2010-02-16 | 2016-01-20 | 诺沃—诺迪斯克有限公司 | 缀合蛋白质 |
EP2536434B1 (en) | 2010-02-16 | 2016-04-20 | Novo Nordisk A/S | Purification method |
WO2011141407A1 (en) | 2010-05-10 | 2011-11-17 | Novo Nordisk A/S | Process for the preparation of insulin-zinc complexes |
US20130345397A1 (en) | 2010-05-25 | 2013-12-26 | Andrea Robinson | Methods for the synthesis of dicarba bridges in peptides |
US8883722B2 (en) | 2010-06-23 | 2014-11-11 | Novo Nordisk A/S | Human insulin containing additional disulfide bonds |
WO2011161124A1 (en) | 2010-06-23 | 2011-12-29 | Novo Nordisk A/S | Insulin analogues containing additional disulfide bonds |
CA2802510A1 (en) | 2010-06-23 | 2011-12-29 | Novo Nordisk A/S | Insulin derivatives containing additional disulfide bonds |
US20140315797A1 (en) | 2010-10-15 | 2014-10-23 | Peter Madsen | Novel N-Terminally Modified Insulin Derivatives |
RU2013123515A (ru) * | 2010-10-27 | 2014-12-10 | Ново Нордиск А/С | Лечение сахарного диабета с помощью инъекций инсулина, вводимых с различными интервалами |
PL2632478T3 (pl) | 2010-10-27 | 2020-03-31 | Novo Nordisk A/S | Leczenie cukrzycy z zastosowaniem zastrzyków insuliny podawanych w różnych odstępach czasu |
US20130331320A1 (en) | 2010-12-14 | 2013-12-12 | Novo Nordisk A/S | Fast-acting insulin in combination with long-acting insulin |
CN103370075A (zh) | 2011-02-15 | 2013-10-23 | 诺沃—诺迪斯克有限公司 | 长效il-1受体拮抗剂 |
AU2012234276A1 (en) * | 2011-03-28 | 2013-08-29 | Novo Nordisk A/S | Novel glucagon analogues |
CN103458873B (zh) | 2011-04-14 | 2016-04-13 | 诺沃—诺迪斯克有限公司 | 用于口服肽递送的脂肪酸酰化的氨基酸 |
WO2012171994A1 (en) | 2011-06-15 | 2012-12-20 | Novo Nordisk A/S | Multi substituted insulins |
TWI596110B (zh) | 2011-09-23 | 2017-08-21 | 諾佛 儂迪克股份有限公司 | 新穎升糖素類似物 |
US9458219B2 (en) * | 2011-12-15 | 2016-10-04 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Human insulin analogue and acylated derivative thereof |
JP2015502971A (ja) | 2011-12-21 | 2015-01-29 | ノヴォ ノルディスク アー/エス | N末端修飾インスリン誘導体 |
WO2013153000A2 (en) | 2012-04-11 | 2013-10-17 | Novo Nordisk A/S | Insulin formulations |
US20160031962A1 (en) * | 2012-04-20 | 2016-02-04 | Kleomenis K. Barlos | Solid phase peptide synthesis of insulin using side chain achored lysine |
JP6262206B2 (ja) | 2012-05-01 | 2018-01-17 | ノヴォ ノルディスク アー/エス | 医薬組成物 |
EP2869830B1 (en) | 2012-07-09 | 2016-10-12 | Novo Nordisk A/S | Novel use of insulin derivatives |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
US20150265710A1 (en) | 2012-10-17 | 2015-09-24 | Novo Nordisk A/S | Fatty Acid Acylated D-Amino Acids for Oral Peptide Delivery |
ES2688367T3 (es) | 2012-12-21 | 2018-11-02 | Sanofi | Derivados de exendina-4 como agonistas duales de GLP1/GIP o trigonales de GLP1/GIP/glucagón |
JP6755175B2 (ja) * | 2013-03-20 | 2020-09-16 | ノヴォ ノルディスク アー/エス | インスリン投薬レジメン |
WO2014170496A1 (en) | 2013-04-18 | 2014-10-23 | Novo Nordisk A/S | Stable, protracted glp-1/glucagon receptor co-agonists for medical use |
US10137172B2 (en) | 2013-04-30 | 2018-11-27 | Novo Nordisk A/S | Administration regime |
GB201315335D0 (en) | 2013-08-29 | 2013-10-09 | Of Singapore | Amino diacids containing peptide modifiers |
AU2014333979B2 (en) | 2013-10-07 | 2018-02-15 | Novo Nordisk A/S | Novel derivative of an insulin analogue |
FR3013049B1 (fr) | 2013-11-14 | 2015-11-13 | You-Ping Chan | Analogue de l'insuline glargine |
TW201609795A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 作為雙重glp-1/gip受體促效劑的艾塞那肽-4(exendin-4)胜肽類似物 |
EP3080152A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Non-acylated exendin-4 peptide analogues |
EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
CN106029088A (zh) | 2014-02-18 | 2016-10-12 | 诺和诺德股份有限公司 | 稳定的胰高血糖素类似物以及用于治疗低血糖的用途 |
AR099569A1 (es) | 2014-02-28 | 2016-08-03 | Novo Nordisk As | Derivados de insulina y los usos médicos de estos |
TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自exendin-4之雙重glp-1/升糖素受體促效劑 |
TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑 |
CN106536547A (zh) | 2014-06-04 | 2017-03-22 | 诺和诺德股份有限公司 | 用于医疗用途的glp‑1/胰高血糖素受体共激动剂 |
US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物 |
JP2018531899A (ja) | 2015-08-25 | 2018-11-01 | ノヴォ ノルディスク アー/エス | 新規インスリン誘導体及びその医学的使用 |
CN108026156A (zh) | 2015-08-25 | 2018-05-11 | 诺和诺德股份有限公司 | 新型胰岛素衍生物及其医学用途 |
EP3495384A4 (en) * | 2016-08-02 | 2020-02-26 | Jiangsu Hengrui Medicine Co., Ltd. | ACYLATED DERIVATIVE OF HUMAN INSULIN OR ANALOGUE OF IT |
WO2018096164A1 (en) | 2016-11-28 | 2018-05-31 | Novo Nordisk A/S | Insulin degludec for treating diabetes |
CN110022935A (zh) | 2016-11-28 | 2019-07-16 | 诺和诺德股份有限公司 | 用于心血管病况的德谷胰岛素 |
CN110099719A (zh) | 2016-11-28 | 2019-08-06 | 诺和诺德股份有限公司 | 用于改善血糖控制以及减少急性和长期糖尿病并发症的德谷胰岛素 |
HUE055231T2 (hu) | 2016-12-16 | 2021-11-29 | Novo Nordisk As | Inzulint tartalmazó gyógyászati készítmények |
JOP20190273A1 (ar) | 2017-05-26 | 2019-11-24 | Lilly Co Eli | مركب إنسولين معالج بأسيل |
AU2019218315A1 (en) | 2018-02-09 | 2020-07-09 | Jiangsu Hengrui Medicine Co., Ltd. | Codon optimized precursor gene and signal peptide gene of human insulin analogue |
BR112020023485A2 (pt) | 2018-05-24 | 2021-03-30 | Jiangsu Hengrui Medicine Co., Ltd. | Métodos para preparar um precursor de insulina humana recombinante ou análogo da mesma, insulina humana recombinante ou análogo da mesma e análogo de insulina acilado |
EP3815106A1 (en) | 2018-06-26 | 2021-05-05 | Novo Nordisk A/S | System providing dose recommendations for basal insulin titration |
US10335464B1 (en) | 2018-06-26 | 2019-07-02 | Novo Nordisk A/S | Device for titrating basal insulin |
KR20200017078A (ko) | 2018-08-08 | 2020-02-18 | 주식회사 대웅제약 | 지속형 인슐린 아날로그 및 그 복합체 |
KR20200080748A (ko) | 2018-12-27 | 2020-07-07 | 주식회사 폴루스 | 음이온 교환 크로마토그래피를 이용한 인슐린 전구체의 정제방법 |
KR20200080747A (ko) | 2018-12-27 | 2020-07-07 | 주식회사 폴루스 | 인슐린 전구체의 인슐린 효소 전환용 조성물 및 이를 이용하여 인슐린 전구체를 인슐린으로 전환하는 방법 |
TW202120536A (zh) | 2019-07-31 | 2021-06-01 | 美商美國禮來大藥廠 | 鬆弛素(relaxin)類似物及其使用方法 |
MX2022008130A (es) | 2019-12-30 | 2022-10-03 | Gan & Lee Pharmaceuticals Co Ltd | Derivado de insulina. |
WO2023084118A1 (en) | 2021-11-15 | 2023-05-19 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
EP4180060A1 (en) | 2021-11-15 | 2023-05-17 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
EP4299057A1 (en) | 2022-06-30 | 2024-01-03 | Adocia | Solid compositions comprising a peptide or a protein and an acylated amino acid |
EP4299071A1 (en) | 2022-07-01 | 2024-01-03 | Adocia | Compositions comprising a peptide or a protein and an acylated amino acid |
Family Cites Families (95)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1212679B (de) | 1957-08-03 | 1966-03-17 | Novo Terapeutisk Labor As | Verfahren zur Herstellung von Insulinloesungen |
GB1042194A (en) | 1962-04-30 | 1966-09-14 | Olin Mathieson | Insulin preparations |
US3528960A (en) | 1968-10-07 | 1970-09-15 | Lilly Co Eli | N-carboxyaroyl insulins |
US3868358A (en) * | 1971-04-30 | 1975-02-25 | Lilly Co Eli | Protamine-insulin product |
GB1492997A (en) | 1976-07-21 | 1977-11-23 | Nat Res Dev | Insulin derivatives |
JPS5767548A (en) | 1980-10-14 | 1982-04-24 | Shionogi & Co Ltd | Insulin analog and its preparation |
FI78616C (fi) * | 1982-02-05 | 1989-09-11 | Novo Industri As | Foerfarande foer framstaellning av en foer infusionsaendamaol avsedd stabiliserad insulinloesning, som har en foerhoejd zinkhalt. |
PH25772A (en) | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
NZ222907A (en) | 1986-12-16 | 1990-08-28 | Novo Industri As | Preparation for intranasal administration containing a phospholipid absorption enhancing system |
US5605884A (en) * | 1987-10-29 | 1997-02-25 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Factor VIII formulations in high ionic strength media |
US4877608A (en) | 1987-11-09 | 1989-10-31 | Rorer Pharmaceutical Corporation | Pharmaceutical plasma protein formulations in low ionic strength media |
JPH01254699A (ja) | 1988-04-05 | 1989-10-11 | Kodama Kk | インスリン誘導体及びその用途 |
DE3827533A1 (de) * | 1988-08-13 | 1990-02-15 | Hoechst Ag | Pharmazeutische zubereitung zur behandlung des diabetes mellitus |
KR910700262A (ko) | 1988-12-23 | 1991-03-14 | 안네 제케르 | 사람 인슐린 유사체 |
NZ232375A (en) | 1989-02-09 | 1992-04-28 | Lilly Co Eli | Insulin analogues modified at b29 |
IT1240314B (it) | 1989-09-28 | 1993-12-07 | Immunobiology Research Institutes, Inc. | Formulazioni acquose stabilizzate di piccoli peptidi. |
DE69019534T2 (de) * | 1989-12-21 | 1995-09-21 | Novo Nordisk As | Insulinzubereitungen, die nikotinsäure oder nikotinamid enthalten. |
DK45590D0 (un) | 1990-02-21 | 1990-02-21 | Novo Nordisk As | |
JP3193398B2 (ja) | 1991-07-23 | 2001-07-30 | サンデン株式会社 | ショ−ケ−ス |
ATE227583T1 (de) | 1991-12-20 | 2002-11-15 | Novo Nordisk As | Stabilisierte pharmazeutische formulierung, die wachstumshormon und histidin enthält |
US6011007A (en) * | 1993-09-17 | 2000-01-04 | Novo Nordisk A/S | Acylated insulin |
ATE204882T1 (de) | 1993-09-17 | 2001-09-15 | Novo Nordisk As | Acyliertes insulin |
US6869930B1 (en) * | 1993-09-17 | 2005-03-22 | Novo Nordisk A/S | Acylated insulin |
US5652216A (en) | 1994-05-26 | 1997-07-29 | Novo Nordisk A/S | Pharmaceutical preparation |
WO1996010417A1 (en) | 1994-10-04 | 1996-04-11 | Novo Nordisk A/S | PREPARATIONS CONTAINING AspB28 HUMAN INSULIN AND NICOTINAMIDE |
US5646242A (en) * | 1994-11-17 | 1997-07-08 | Eli Lilly And Company | Selective acylation of epsilon-amino groups |
US5830999A (en) * | 1995-01-26 | 1998-11-03 | Regents Of The University Of California | Stabilization of insulin through ligand binding interations |
BR9607647A (pt) | 1995-03-17 | 1999-04-06 | Novo Nordisk As | Derivado de insulina e composição farmacêutica e processo para o tratamento de diabetes em um paciente em necessidade deste tratamento |
US6251856B1 (en) * | 1995-03-17 | 2001-06-26 | Novo Nordisk A/S | Insulin derivatives |
CA2226575C (en) | 1995-07-27 | 2011-10-18 | Genentech, Inc. | Stabile isotonic lyophilized protein formulation |
US6451970B1 (en) * | 1996-02-21 | 2002-09-17 | Novo Nordisk A/S | Peptide derivatives |
US5898267A (en) * | 1996-04-10 | 1999-04-27 | Mcdermott; Kevin | Parabolic axial lighting device |
US5866538A (en) * | 1996-06-20 | 1999-02-02 | Novo Nordisk A/S | Insulin preparations containing NaCl |
EP0938502B1 (en) * | 1996-07-11 | 2004-10-06 | Novo Nordisk A/S | Selective acylation method |
US5905140A (en) * | 1996-07-11 | 1999-05-18 | Novo Nordisk A/S, Novo Alle | Selective acylation method |
US5763401A (en) | 1996-07-12 | 1998-06-09 | Bayer Corporation | Stabilized albumin-free recombinant factor VIII preparation having a low sugar content |
ES2218622T3 (es) * | 1996-07-26 | 2004-11-16 | Aventis Pharma Deutschland Gmbh | Derivados de insulina con actividad de union al zinc incrementada. |
IL119029A0 (en) | 1996-08-07 | 1996-11-14 | Yeda Res & Dev | Long-acting drugs and pharamaceutical compositions comprising them |
US5898067A (en) * | 1997-02-07 | 1999-04-27 | Novo Nordisk A/S | Crystallization of proteins |
WO1998042749A1 (en) * | 1997-03-20 | 1998-10-01 | Novo Nordisk A/S | Zinc free insulin crystals for use in pulmonary compositions |
EP0969860B1 (en) | 1997-03-20 | 2002-07-17 | Novo Nordisk A/S | Method for preparation of a therapeutic powder through coprecipitation of insulin and absorption enhancer |
WO1998042368A1 (en) | 1997-03-20 | 1998-10-01 | Novo Nordisk A/S | Therapeutic powder formulation for pulmonary administration, containing crystalline insulin |
US7097845B2 (en) | 1997-04-23 | 2006-08-29 | Jacob Sten Petersen | Combinations of antigen and mucosal binding component for inducing specific immunological tolerance |
EP1283051B1 (en) | 1997-06-13 | 2006-06-14 | Eli Lilly And Company | Stable insulin formulations |
US6451762B1 (en) * | 1997-10-24 | 2002-09-17 | Novo Nordisk A/S | Aggregates of human insulin derivatives |
US20020155994A1 (en) * | 1997-10-24 | 2002-10-24 | Svend Havelund | Aggregates of human insulin derivatives |
EP1039920A4 (en) | 1997-10-24 | 2003-05-28 | Lilly Co Eli | INSULIN ANALOGS ACYLATED BY FATTY ACID |
PL195845B1 (pl) * | 1997-10-24 | 2007-10-31 | Novo Nordisk As | Rozpuszczalny w wodzie agregat pochodnych insuliny |
ZA989744B (en) * | 1997-10-31 | 2000-04-26 | Lilly Co Eli | Method for administering acylated insulin. |
US6531448B1 (en) | 1997-12-23 | 2003-03-11 | Eli Lilly And Company | Insoluble compositions for controlling blood glucose |
DE69924232D1 (de) * | 1998-01-09 | 2005-04-21 | Novo Nordisk As | Stabilisierte insulin-zubereitungen |
DK1121144T3 (da) | 1998-10-16 | 2002-09-23 | Novo Nordisk As | Stabile koncentrerede insulinpræparater til pulmonar indgivelse |
US6211144B1 (en) * | 1998-10-16 | 2001-04-03 | Novo Nordisk A/S | Stable concentrated insulin preparations for pulmonary delivery |
PT2130554E (pt) * | 1999-02-22 | 2012-11-19 | Univ Connecticut | Formulações de factor viii isentas de albumina |
AU4450700A (en) | 1999-04-27 | 2000-11-10 | Eli Lilly And Company | Insulin crystals for pulmonary administration |
GB9930882D0 (en) | 1999-12-30 | 2000-02-23 | Nps Allelix Corp | GLP-2 formulations |
DE10022092A1 (de) | 2000-05-08 | 2001-11-15 | Aventis Behring Gmbh | Stabilisiertes Protein-Präparat und Verfahren zu seiner Herstellung |
US6652886B2 (en) * | 2001-02-16 | 2003-11-25 | Expression Genetics | Biodegradable cationic copolymers of poly (alkylenimine) and poly (ethylene glycol) for the delivery of bioactive agents |
DE10114178A1 (de) | 2001-03-23 | 2002-10-10 | Aventis Pharma Gmbh | Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität |
DE60224284T2 (de) | 2001-06-28 | 2008-12-18 | Novo Nordisk A/S | Stabile formulierung von modifiziertem glp-1 |
EP1545460A4 (en) | 2001-12-20 | 2005-11-16 | Lilly Co Eli | INSULIN MOLECULE WITH TEMPORARY EFFECT |
AU2003208316A1 (en) * | 2002-03-13 | 2003-09-22 | Novo Nordisk A/S | Minimising body weight gain in insulin treatment |
ES2360182T3 (es) * | 2002-05-07 | 2011-06-01 | Novo Nordisk A/S | Formulaciones solubles que comprenden insulina monomérica e insulina acilada. |
US20050232899A1 (en) * | 2002-05-31 | 2005-10-20 | Aradigm Corporation | Compositions methods and systems for pulmonary delivery of recombinant human interferon alpha-2b |
US20040002451A1 (en) * | 2002-06-20 | 2004-01-01 | Bruce Kerwin | Compositions of pegylated soluble tumor necrosis factor receptors and methods of preparing |
KR100615389B1 (ko) | 2002-08-23 | 2006-08-25 | (주)헬릭서 | 다래 추출물을 함유하는 알러지성 질환 및 비알러지성염증 질환의 예방 및 개선용 건강 기능 식품 |
JP2006504772A (ja) | 2002-10-29 | 2006-02-09 | アルザ・コーポレーション | 安定化された固体ポリペプチド粒子 |
US20040138099A1 (en) * | 2002-11-29 | 2004-07-15 | Draeger Eberhard Kurt | Insulin administration regimens for the treatment of subjects with diabetes |
MXPA05008363A (es) | 2003-02-07 | 2005-12-06 | Ajinomoto Kk | Agentes terapeuticos para diabetes. |
EP1597367B1 (en) | 2003-02-19 | 2010-07-07 | Novartis AG | Glycoprotein antigen sima135 expressed in metastatic human tumor cells |
EP1454630B1 (en) * | 2003-03-04 | 2010-10-20 | The Technology Development Company Ltd. | Long acting injectable insulin composition and methods of making and using thereof |
ES2382157T3 (es) | 2003-06-25 | 2012-06-05 | Novo Nordisk Health Care Ag | Composición líquida de polipépttidos del factor VII |
US20050054818A1 (en) * | 2003-07-02 | 2005-03-10 | Brader Mark Laurence | Crystalline compositions for controlling blood glucose |
BRPI0413276B8 (pt) | 2003-08-05 | 2021-05-25 | Novo Nordisk As | derivado de insulina, complexo de zinco do mesmo, e, composição farmacêutica |
PT2107069E (pt) | 2003-08-05 | 2013-04-23 | Novo Nordisk As | Novos derivados de insulina |
ES2574581T3 (es) | 2003-08-14 | 2016-06-20 | Novo Nordisk Health Care Ag | Composición farmacéutica líquida acuosa de polipéptidos de tipo Factor VII |
WO2005021022A2 (en) | 2003-09-01 | 2005-03-10 | Novo Nordisk A/S | Stable formulations of peptides |
ES2229931B1 (es) * | 2003-10-03 | 2006-01-16 | Grifols, S.A. | Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos. |
JP2007532096A (ja) * | 2003-11-14 | 2007-11-15 | ノボ ノルディスク アクティーゼルスカブ | アシル化されたインスリンの製造方法 |
ES2383691T3 (es) | 2003-12-23 | 2012-06-25 | Pharmacia Corporation | Formulación líquida estable de hormonas de crecimiento |
PL1740154T3 (pl) | 2004-03-12 | 2009-11-30 | Biodel Inc | Kompozycje insuliny o ulepszonym wchłanianiu |
WO2005117948A1 (en) | 2004-06-01 | 2005-12-15 | Ares Trading S.A. | Method of stabilizing proteins |
DE602005022895D1 (de) | 2004-08-12 | 2010-09-23 | Schering Corp | Stabile pegylierte interferon-formulierung |
PT1778723E (pt) | 2004-08-17 | 2013-01-25 | Regeneron Pharma | Formulações de antagonista de il-1 |
ES2575984T3 (es) | 2004-11-12 | 2016-07-04 | Novo Nordisk A/S | Formulaciones estables de péptidos que contienen un análogo de GLP-1 acilado y una insulina basal |
JP4874989B2 (ja) | 2004-11-22 | 2012-02-15 | ノヴォ ノルディスク アー/エス | 可溶性で安定なインスリン含有調合物 |
EP1838290A2 (en) | 2005-01-21 | 2007-10-03 | Alza Corporation | Therapeutic peptide formulations for coating microneedles with improved stability containing at least one counterion |
WO2006082204A1 (en) * | 2005-02-02 | 2006-08-10 | Novo Nordisk A/S | Insulin derivatives |
EP2505593A1 (en) | 2005-12-28 | 2012-10-03 | Novo Nordisk A/S | Compositions comprising an acylated insulin and zinc and method of making the said compositions |
ATE482977T1 (de) * | 2006-02-27 | 2010-10-15 | Novo Nordisk As | Insulinderivate |
MX2008013165A (es) | 2006-04-12 | 2009-01-29 | Biodel Inc | Formulaciones de combinacion de insulina de accion rapida y accion larga. |
KR101441444B1 (ko) * | 2006-05-09 | 2014-09-18 | 노보 노르디스크 에이/에스 | 인슐린 유도체 |
WO2008152106A1 (en) * | 2007-06-13 | 2008-12-18 | Novo Nordisk A/S | Pharmaceutical formulation comprising an insulin derivative |
ES2430042T3 (es) * | 2007-11-16 | 2013-11-18 | Novo Nordisk A/S | Composiciones farmacéuticas estables que comprenden liraglutida y degludec |
TWI451876B (zh) * | 2008-06-13 | 2014-09-11 | Lilly Co Eli | 聚乙二醇化之離脯胰島素化合物 |
-
2004
- 2004-07-22 BR BRPI0413276A patent/BRPI0413276B8/pt active IP Right Grant
- 2004-07-22 PL PL09165072T patent/PL2107069T3/pl unknown
- 2004-07-22 MX MXPA06001283A patent/MXPA06001283A/es active IP Right Grant
- 2004-07-22 AU AU2004261353A patent/AU2004261353B2/en active Active
- 2004-07-22 EP EP04739008A patent/EP1660531A2/en not_active Withdrawn
- 2004-07-22 KR KR1020067002551A patent/KR101159559B1/ko active Protection Beyond IP Right Term
- 2004-07-22 WO PCT/DK2004/000511 patent/WO2005012347A2/en active Application Filing
- 2004-07-22 EP EP09165072A patent/EP2107069B1/en active Active
- 2004-07-22 CA CA2531988A patent/CA2531988C/en not_active Expired - Fee Related
- 2004-07-22 JP JP2006522233A patent/JP4463814B2/ja active Active
- 2004-07-22 EP EP10174490.2A patent/EP2264065B1/en active Active
-
2006
- 2006-01-05 IL IL172980A patent/IL172980A/en active Protection Beyond IP Right Term
- 2006-01-30 US US11/343,005 patent/US7615532B2/en active Active
- 2006-03-02 NO NO20061026A patent/NO340925B1/no active Protection Beyond IP Right Term
-
2008
- 2008-12-29 RU RU2008152033/04A patent/RU2518460C2/ru active
-
2009
- 2009-09-16 US US12/560,833 patent/US8828923B2/en active Active
-
2010
- 2010-02-10 AU AU2010200497A patent/AU2010200497B2/en active Active
-
2013
- 2013-03-28 CY CY20131100259T patent/CY1113850T1/el unknown
- 2013-06-10 LU LU92213C patent/LU92213I2/fr unknown
- 2013-06-11 BE BE2013C035C patent/BE2013C035I2/fr unknown
- 2013-06-19 BE BE2013C038C patent/BE2013C038I2/fr unknown
- 2013-06-19 LU LU92226C patent/LU92226I2/xx unknown
- 2013-07-04 FR FR13C0035C patent/FR13C0035I2/fr active Active
- 2013-07-04 CY CY2013027C patent/CY2013027I2/el unknown
- 2013-07-08 CY CY2013029C patent/CY2013029I1/el unknown
- 2013-07-18 HU HUS1300033C patent/HUS1300033I1/hu unknown
-
2014
- 2014-08-06 US US14/453,276 patent/US20140349925A1/en not_active Abandoned
-
2018
- 2018-01-11 NO NO2018002C patent/NO2018002I2/no unknown
- 2018-01-11 NO NO2018003C patent/NO2018003I1/no unknown